Literature DB >> 7578077

Isolation and structural characterization of different isoforms of the hypusine-containing protein eIF-5A from HeLa cells.

H Klier1, R Csonga, H C Joäo, C Eckerskorn, M Auer, F Lottspeich, J Eder.   

Abstract

Posttranslational modification of a specific lysine residue in eukaryotic initiation factor 5A (eIF-5A) is essential for cell viability and proliferation. The product of this modification is hypusine, an amino acid unique to eIF-5A. We have purified and characterized one major and three minor isoforms of human eIF-5A from HeLa cells. The main form, which accounts for approximately 95% of the total eIF-5A, carries hypusine at position 50 and is amino-terminally acetylated as determined by amino acid composition analysis and electrospray ionization mass spectrometry. Analytical gel filtration indicates that this protein variant possesses a native apparent molecular weight that lies between that expected for a monomeric and dimeric form. Nevertheless, several experiments confirm this protein to be monomeric. It is further shown that eIF-5A have well-defined secondary structure. Both the far-UV circular dichroism spectrum as well as secondary structure predictions using different algorithms suggest this protein to have predominantly beta-sheet structure. Two plausible models for the packing of the secondary structure elements are presented. In contrast to the main form, all three minor isoforms of eIF-5A are characterized by acetylation of the epsilon-amino group of lysine at position 47. The minor isoforms are distinguishable by their state of modification of the lysine residue at position 50. Whereas the main form occurs in both the cytoplasmic and the nuclear fraction of HeLa cells, the minor isoforms were not detectable in the preparation of the nuclear fraction. Therefore, acetylation of lysine at position 47 might play a controlling role in the distribution of the minor isoforms to the nucleus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7578077     DOI: 10.1021/bi00045a010

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  18 in total

1.  Inhibition of eIF5A results in aberrant uterine natural killer cell function and embryo loss in mice.

Authors:  Xiaoli Qin; Xiaorui Liu; Bin Shan; Lijuan Shi; Surendra Sharma; Ji Wu; Yi Lin
Journal:  Am J Reprod Immunol       Date:  2014-01-02       Impact factor: 3.886

2.  Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy.

Authors:  Ilona Hauber; Dorian Bevec; Jochen Heukeshoven; Friedrich Krätzer; Florian Horn; Axel Choidas; Thomas Harrer; Joachim Hauber
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

3.  Deoxyhypusine synthase haploinsufficiency attenuates acute cytokine signaling.

Authors:  Andrew T Templin; Bernhard Maier; Yurika Nishiki; Sarah A Tersey; Raghavendra G Mirmira
Journal:  Cell Cycle       Date:  2011-04-01       Impact factor: 4.534

4.  Independent roles of eIF5A and polyamines in cell proliferation.

Authors:  Kazuhiro Nishimura; Kaori Murozumi; Akira Shirahata; Myung Hee Park; Keiko Kashiwagi; Kazuei Igarashi
Journal:  Biochem J       Date:  2005-02-01       Impact factor: 3.857

5.  The effect of hypusine modification on the intracellular localization of eIF5A.

Authors:  Seung Bum Lee; Jong Hwan Park; Jörn Kaevel; Monika Sramkova; Roberto Weigert; Myung Hee Park
Journal:  Biochem Biophys Res Commun       Date:  2009-04-18       Impact factor: 3.575

6.  Modulation of eIF5A expression using SNS01 nanoparticles inhibits NF-κB activity and tumor growth in murine models of multiple myeloma.

Authors:  Catherine A Taylor; Zhongda Liu; Terence C Tang; Qifa Zheng; Sarah Francis; Tzann-Wei Wang; Bin Ye; John A Lust; Richard Dondero; John E Thompson
Journal:  Mol Ther       Date:  2012-05-15       Impact factor: 11.454

7.  Recessive Rare Variants in Deoxyhypusine Synthase, an Enzyme Involved in the Synthesis of Hypusine, Are Associated with a Neurodevelopmental Disorder.

Authors:  Mythily Ganapathi; Leah R Padgett; Kentaro Yamada; Orrin Devinsky; Rebecca Willaert; Richard Person; Ping-Yee Billie Au; Julia Tagoe; Marie McDonald; Danielle Karlowicz; Barry Wolf; Joanna Lee; Yufeng Shen; Volkan Okur; Liyong Deng; Charles A LeDuc; Jiayao Wang; Ashleigh Hanner; Raghavendra G Mirmira; Myung Hee Park; Teresa L Mastracci; Wendy K Chung
Journal:  Am J Hum Genet       Date:  2019-01-17       Impact factor: 11.025

8.  Identification of Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) target proteins by proteome analysis: activation of EBNA2 in conditionally immortalized B cells reflects early events after infection of primary B cells by EBV.

Authors:  Martin Schlee; Tanja Krug; Olivier Gires; Reinhard Zeidler; Wolfgang Hammerschmidt; Reinhard Mailhammer; Gerhard Laux; Guido Sauer; Josip Lovric; Georg W Bornkamm
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

9.  Blocking eIF5A modification in cervical cancer cells alters the expression of cancer-related genes and suppresses cell proliferation.

Authors:  Elisabeth Mémin; Mainul Hoque; Mohit R Jain; Debra S Heller; Hong Li; Bernadette Cracchiolo; Hartmut M Hanauske-Abel; Tsafi Pe'ery; Michael B Mathews
Journal:  Cancer Res       Date:  2013-11-12       Impact factor: 12.701

10.  Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A.

Authors:  Mainul Hoque; Hartmut M Hanauske-Abel; Paul Palumbo; Deepti Saxena; Darlene D'Alliessi Gandolfi; Myung Hee Park; Tsafi Pe'ery; Michael B Mathews
Journal:  Retrovirology       Date:  2009-10-13       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.